Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Owlstone Medical
Owlstone Medical
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
Therapeutic: ensifentrine for chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) comes in various guises, including chronic bronchitis and emphysema; and, although incurable, the symptoms can be managed with...
Merck’s clesrovimab meets all primary endpoints in Phase IIb/III trial for RSV in infants
A teaser of the Phase IIb/III trial released by Merck indicates that clesrovimab can reduce the need to medically attend lower respiratory infections caused by RSV in infants
Bringing biotech to the Baltics: the rise of Lithuania
Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a...
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Research & Development
Owlstone Medical bags $6.5m to optimise infectious disease diagnostic tool
The Bill & Melinda Gates Foundation has funded the bolstering of the Breath Biopsy platform, as well as research into breath biomarkers in tuberculosis (TB) and HIV
Regulatory
Owlstone wins contract for disease detection devices
The ‘EXHALE’ project, focused on the early detection of human infection using volatile organic compounds (VOCs) on breath, will develop a handheld device
Finance
Owlstone Medical closes $58m financing round
The funding will be used to advance the company's proprietary platform for early disease detection and precision medicine
Regulatory
Clinical trial launches to develop breath test for multiple cancers
Researchers have launched a clinical trial to develop a breath test, analysing molecules that could indicate the presence of cancer at an early stage
Recruitment
Owlstone Medical appoints Dr Andy Richards to board
Research & Development
Owlstone Medical appoints five experts to Scientific Advisory Board
The additions form a key strategic resource to advise on Breath Biopsy platform, product and study development
Research & Development
Owlstone Medical provides Breath Biopsy Services to AstraZeneca to study disease drivers in Asthma and COPD
Collaboration will explore use of Breath Biopsy to identify novel biomarkers to enable personalised medicine applications
Subscribe now